Peer-reviewed article
Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression.
Gupta RM, Ismail HM, Siller AF, Pesikoff J, Devaraj S et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical review article about type 1 diabetes development in relation to body size and obesity. It discusses genetic and environmental factors in diabetes onset, with emphasis on how body mass index and adiposity affect disease progression through preclinical stages. The article notes that associations between obesity and diabetes vary by age, ethnicity, and genetic background, and calls for further research into the biological mechanisms and potential prevention strategies.
Key points
- Elevated BMI and adiposity are linked to onset of islet autoimmunity and progression to clinical type 1 diabetes
- Susceptibility to obesity-related diabetes risk is higher in younger children, Hispanic populations, and those with specific HLA genotypes
- Proposed biological pathways include insulin resistance, β-cell stress, adipose tissue inflammation, altered adipokine signaling, and gut microbiome changes
- Disease-modifying therapies can delay progression but show inconsistent and transient responses
- Future research should evaluate whether reducing BMI or targeting obesity-associated pathways can alter disease trajectory
Limitations
This is a narrative review article that synthesizes existing epidemiologic and mechanistic evidence rather than presenting new empirical data or evaluating a specific intervention. It does not provide information on implementation of prevention strategies or their effectiveness.
Abstract
Type 1 diabetes arises from the interplay of genetic susceptibility and environmental exposures, leading to autoimmune β-cell destruction. Although disease-modifying therapies (DMTs) can delay progression to clinical (stage 3) type 1 diabetes, treatment responses remain inconsistent and transient. The marked heterogeneity of type 1 diabetes, shaped by age, sex, race or ethnicity, and genetic background, underscores the need to elucidate distinct mechanistic pathways. Among environmental contributors, obesity stands out as a compelling modifiable target. Data from The Environmental Determinants of Diabetes in the Young (TEDDY), Type 1 Diabetes TrialNet, and other longitudinal cohorts link BMI and adiposity to the onset of islet autoimmunity, progression through preclinical stages, and development of stage 3 type 1 diabetes. These associations are not uniform; heightened susceptibility to adiposity-related risk is seen among younger children, Hispanic populations, and individuals with specific HLA genotypes. Despite robust epidemiologic evidence, the biological pathways connecting elevated BMI to autoimmune β-cell destruction remain incompletely defined. Emerging data implicate a network of immunologic and metabolic disturbances, including insulin resistance, β-cell stress, chronic adipose tissue inflammation, altered adipokine signaling, and gut microbiome changes, that collectively heighten β-cell vulnerability, amplify autoreactive immune responses, and drive metabolic decompensation toward clinical disease. Elucidating these mechanisms and identifying related biomarkers are critical to advancing precision prevention. In future studies, investigators should evaluate whether modifying elevated BMI or targeting obesity-associated immunologic and metabolic pathways can alter the preclinical trajectory of type 1 diabetes. Such mechanistic understanding may help curb type 1 diabetes incidence and improve outcomes for populations most vulnerable to obesity-related risk.